Adherence can decrease hospitalizations for inflammatory bowel diseases

Adherence to high-cost biologic therapies are associated with two-fold decrease in hospitalizations for key inflammatory bowel diseases

This study showed that members with Crohn’s disease or ulcerative colitis who were adherent to biologic therapy had approximately two-fold lower odds of hospitalization. Hospitalizations are costly from a direct and indirect cost perspective. To prevent one hospitalization through improved adherence, plans would incur substantial additional biologic therapy cost. It’s important to consider these findings in clinical care programs and as justification in value-based contracting.

Association Between Hospitalization for Crohn’s Disease (CD) or Ulcerative Colitis (UC) and Biologic Drug Therapy Adherence (March 2019)

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit www.primetherapeutics.com and www.magellanrx.com, or follow us on Twitter at @Prime_PBM and @Magellan_Rx.

Adherence can decrease hospitalizations for inflammatory bowel diseases

Association Between Hospitalization for Crohn’s Disease (CD) or Ulcerative Colitis (UC) and Biologic Drug Therapy Adherence (March 2019)

About Prime Therapeutics

Related news

Specialty Drug Pipeline Quarterly Update: September 2023

Traditional Drug Pipeline Quarterly Update: September 2023

Gene/Cell Therapy Quarterly Update: September 2023